An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2001

This article is included in 4 Systematic reviews Systematic reviews (4 references) 2 Broad syntheses Broad syntheses (2 references)

This article is part of the following publication threads:
This article is part of the following matrixes of evidence:
Loading references information
A study to compare the efficacy of GW-1000-02 \[named Sativex® in Canada and also named Sativex® Oromucosal Spray\] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.
Epistemonikos ID: 5eeb9d74462801c4bd906f813ac952651237a783
First added on: Jun 26, 2015